Association between serum hepcidin‐25 and primary resistance to erythropoiesis‐stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial

导出原文传递

翻译打印收藏纠错

作者： Gummer Joel ^[1] ; Trengove Robert ^[2] ; Pascoe Elaine M. ^[3] ; Badve Sunil V. ^[4] ; Cass Alan ^[5] ; Clarke Philip ^[6] ; McDonald Stephen P. ^[7] ; Morrish Alicia T. ^[8] ; Pedagogos Eugenie ; Perkovic Vlado ; Reidlinger Donna ; Scaria Anish ; Walker Rowan ; Vergara Liza A. ; Hawley Carmel M. ; Johnson David W. ; Olynyk John K. ; Ferrari Paolo ; on behalf of the HERO Study Collaborative Group

作者单位： Australasian Kidney Trials NetworkUniversity of QueenslandBrisbane,Australia ^[1] Separation Science and Metabolomics Laboratory and Metabolomics AustraliaMurdoch University ^[2] Department of Nephrology and Transplantation ServicesUniversity of Adelaide at Central Northern ^[3] Department of Renal MedicineThe Alfred HospitalMelbourne,Australia ^[4] Department of NephrologyRoyal Melbourne HospitalMelbourne,Australia ^[5] Department of Gastroenterology, Fremantle and Fiona Stanley HospitalsPerth,Australia ^[6] Centre for Health Policy, Programs and EconomicsUniversity of MelbourneMelbourne,Australia ^[7] Department of NephrologyPrince of Wales HospitalSydney,Australia ^[8]

关键词 erythropoiesis stimulating agents anaemia chronic kidney disease hepcidin‐25 randomised controlled trial

发布时间 2019-03-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交